CRISPR/Cas9 targeting of HIF-1α could be a means of overcoming NK-cell-function-suppressive hypoxia circumstances in NK-cell-based immunotherapy for cancer, including glioblastoma (GBM). Here, HIF1A is linked to glioblastoma.